LumiraDx Ltd
NASDAQ:LMDX
LumiraDx Ltd
Research & Development
LumiraDx Ltd
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LumiraDx Ltd
NASDAQ:LMDX
|
Research & Development
-$131.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Smith & Nephew PLC
LSE:SN
|
Research & Development
-$299m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
LivaNova PLC
NASDAQ:LIVN
|
Research & Development
-$189.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-15%
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Angle PLC
LSE:AGL
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Creo Medical Group PLC
LSE:CREO
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LumiraDx Ltd's Research & Development?
Research & Development
-131.7m
USD
Based on the financial report for Dec 31, 2022, LumiraDx Ltd's Research & Development amounts to -131.7m USD.
What is LumiraDx Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
-16%
Over the last year, the Research & Development growth was -6%. The average annual Research & Development growth rates for LumiraDx Ltd have been -16% over the past three years .